Thera-SAbDab

ABCIXIMAB

>   Structural Summary
TherapeuticAbciximab
TargetCD41_CD61
Heavy ChainEVQLQQSGTVLARPGASVKMSCEASGYTFTNYWMHWVKQRPGQGLEWIGAIYPGNSDTSYIQKFKGKAKLTAVTSTTSVYMELSSLTNEDSAVYYCTLYDGYYVFAYWGQGTLVTVSA
Light ChainEIVLTQSPVTLSVTPGDSVSLSCRASRDISNNLHWFQQTSHESPRLLIKYASQSMSGIPSRFSGSGSGTDFTLSINSVETEDFGMYFCQQTNSWPYTFGGGTKLEIK
100% seqID Fv Structure6v4p [Fvs: CD]
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatFab
IsotypeG1
Highest Clinical Trial (October '21)Approved
Estimated Status (October '21)NFD
Recorded Developmental Technologyna
INN Year Proposed1993
INN Year Recommended1994
Companies InvolvedJanssen Biologics BV, Eli Lilly
Conditions ApprovedCoronary artery restenosis, Unstable angina pectoris
Conditions Activena
Conditions DiscontinuedArterial occlusive disorders, Myocardial infarction, Stroke
NotesSequence sourced through DrugBank.

SAbDab papers

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

Dunbar, J., Krawczyk, K. et al. (2014) SAbDab: the Structural Antibody Database. Nucleic Acids Res. 42(D1):D1140-D1146 [link]

Thera-SAbDab paper

Raybould, M.I.J., Marks, C. et al (2020) Thera-SAbDab: the Therapeutic Structural Antibody Database. Nucleic Acids Res. 48(D1):D383-D388. [link]

Our privacy policy